Breast Cancer Liquid Biopsy Market Size & Share 2024 - 2032

Breast Cancer Liquid Biopsy Market Size

The global breast cancer liquid biopsy market size was valued at USD 305.9 million in 2023 and is estimated to grow at a CAGR of 22.6% from 2024 to 2032. The market has experienced substantial growth driven by the rising incidence of breast cancer and advancements in cancer diagnostic technologies. Innovations such as liquid biopsy and next-generation sequencing (NGS) have gained popularity due to their high accuracy and minimally invasive characteristics.

These advancements are revolutionizing cancer diagnostics by providing precise methods for cancer detection and monitoring. For instance, in 2019, the National Cancer Institute (NCI) reported that liquid biopsies could identify genetic mutations in over 70% of advanced cancer cases, enhancing early detection, supporting personalized treatment strategies, and improving patient outcomes. Thus, the increasing advantages and reliability of non-invasive techniques further bolster market demand.
 

Furthermore, the growing awareness of inherited oncology conditions and genetic testing is fuelling demand for these technologies. This focus on early detection and personalized treatment leads to better patient outcomes, emphasizing targeted cancer therapies that leverage insights from advanced cancer biopsy techniques for diagnosis.
 

Breast cancer liquid biopsy is a non-invasive diagnostic technique that analyzes cancer biomarkers in blood samples to detect and monitor breast cancer. This method focuses on circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), providing insights into tumor characteristics, treatment response, and disease progression. Comparatively, liquid biopsies are easier to perform and can be repeated over time, enabling real-time monitoring of the disease compared to traditional biopsy techniques.
 

Breast Cancer Liquid Biopsy Market Trends

The increasing prevalence of breast cancer, recognized as the second most common cancer type, has substantially fuelled market demand for advanced diagnostic techniques. As cancer cases rise, there is an escalating need for early and targeted diagnostic solutions. This uptick in incidence, coupled with advancements in diagnostic technology, has created a growing demand for non-invasive diagnostic methods that facilitate early detection and effective treatment planning.
 

• For instance, according to the International Agency for Research on Cancer (IARC) 2022 report, female breast cancer is the most common among 20 million new cancer cases worldwide, representing 11.6% of all cases. This increasing incidence has created a significant potential patient population with a pressing need for reliable diagnostic techniques and treatments, thereby bolstering market demand. Consequently, there is a surging need for non-invasive techniques such as liquid biopsy, which are driving market growth.
   
• Additionally, the rising requirement for ongoing screening and diagnostics has significantly expanded the market, as repeat biopsy tests are essential for effective treatment management.
   

Breast Cancer Liquid Biopsy Market Analysis

Based on biomarkers, the market is segmented into circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and other biomarkers. The circulating cell-free DNA (cfDNA) segment dominated the global market and is anticipated to grow at 22.5% CAGR over the forecast period.
 

• The dominance of circulating cell-free DNA (cfDNA) can be attributed to its non-invasive nature and its ability to provide real-time insights into tumor dynamics.
   
• Comprising fragments of DNA released from cancer cells into the bloodstream, cfDNA enables early detection, monitoring of treatment responses, and assessment of disease progression.
   
• Thus, cfDNA’s advantages over traditional tissue biopsies include the capacity to capture a comprehensive genomic landscape and detect emerging mutations associated with drug resistance, thereby propelling its demand.
   
• In addition, recent studies have shown that cfDNA-based diagnostic models exhibit high sensitivity and specificity, outperforming conventional methods like mammography. This growing recognition of cfDNA's clinical efficiency further drives its widespread adoption, making it a prominent feature in the evolving landscape of breast cancer diagnostics and management.
   
• Therefore, the aforementioned factors have strengthened cfDNA's position in the market.

Learn more about the key segments shaping this market

Download Free PDF

Based on the products and services, the breast cancer liquid biopsy market is categorized into kits & reagents and services. The kits & reagents segment accounted for the highest market share of 67.1% in 2023.
 

• The prominence of kits and reagents is underscored by their crucial role in enabling non-invasive cancer diagnostics.
   
• Kits and reagents are essential components of the liquid biopsy process, encompassing sample collection, DNA extraction, and assay execution.
   
• Additionally, the rising incidence of breast cancer has led to a significant increase in demand for these kits for early diagnosis and testing.
   
• Furthermore, continuous research and new product launches aimed at utilizing kits for cancer detection have accelerated market growth. For instance, in April 2023, QIAGEN introduced QIAseq-targeted cfDNA ultra panels to facilitate rapid and easy cancer diagnoses, including breast cancer. The demand for efficient and reliable diagnostic kits highlights the segment's significance.
   
• Moreover, technological advancements and the development of innovative reagents that improve biomarker analysis have reinforced their market position. This trend emphasizes the vital role of kits and reagents in enhancing personalized cancer treatment approaches.
   

Based on sample type, the breast cancer liquid biopsy market is segmented into blood, urine, and other sample types. The blood segment is poised to reach 68.5% by end of 2032.
 

• Blood sample-based liquid biopsy tests offer a minimally invasive and cost-effective method for cancer detection, reducing diagnostic time and expenses.
   
• These tests allow for the identification of circulating biomarkers, including circulating tumor cells (CTCs) and circulating free DNA (cfDNA), which are essential for monitoring tumor behavior and progression. As such, they have become integral to advancing breast cancer diagnostics.
   
• Furthermore, the capability to assess breast cancer stages in real-time through blood samples improves prognostic accuracy and informs treatment decisions, driving increased adoption in clinical practice.
   

Based on end use, the breast cancer liquid biopsy market is segmented into hospitals, cancer research centers, diagnostic centers, and academic & research institutes. The hospital segment dominated the market accounting for USD 141.4 million in 2023.
 

• Hospitals possess the advanced technologies and resources required for liquid biopsy tests, making them a preferred setting for cancer diagnostics.
   
• In addition, the rising prevalence of breast cancer has increased the demand for efficient and rapid diagnostic solutions, prompting hospitals to adopt liquid biopsy methods over traditional tissue biopsies.
   
• Hospitals often function as central hubs for patient management, enabling comprehensive treatment plans that incorporate liquid biopsy results into personalized medicine strategies.
   
• This trend is further supported by ongoing investments in healthcare infrastructure and technology, enhancing hospitals' ability to provide timely and accurate breast cancer diagnostics and strengthening their market position.

The U.S. breast cancer liquid biopsy market accounted for USD 133.3 million in 2023 and is anticipated to grow at a significant growth rate during the forecast period.
 

• The U.S. prominence in the North American market is attributed to its advanced healthcare infrastructure and significant investment in research and development, enabling the rapid adoption of liquid biopsy techniques that offer non-invasive alternatives to traditional biopsies.
   
• Additionally, the increasing incidence of breast cancer has intensified the demand for non-invasive diagnostic techniques. For instance, according to Breastcancer.org, breast cancer accounts for approximately 30% of all newly diagnosed cancers in women in the United States annually. In 2024, an estimated 310,720 women will be diagnosed with invasive breast cancer, with 16% of these cases occurring in women under 50 years old. This increase in cancer cases is expected to drive greater emphasis on early detection and personalized medicine. Combined with the widespread adoption of innovative biopsy technologies, these factors contribute to the growing demand for liquid biopsy in breast cancer diagnoses.
   
• Furthermore, favourable reimbursement policies and a strong emphasis on research and development foster a conducive environment for market growth.
   
• Moreover, the presence of key players in the region, along with ongoing collaborations and product launches, further enhances the U.S.'s leadership in this sector.
   
• Thus, the aforementioned factors underscore the prominence of the U.S. in the North American market.
   

Germany held a prominent position in the Europe breast cancer liquid biopsy market.
 

• Germany’s prominence in the European market is driven by increasing awareness and demand for accurate diagnostic tools.
   
• The country is actively investing in research and clinical studies to address the unmet need for early detection of breast cancer among women.
   
• For instance, the SURVIVE study, funded by the German Federal Ministry of Education and Research, explored the benefits of liquid biopsy-guided follow-up care for early breast cancer patients enrolled in December 2022. This commitment to enhancing cancer detection methods contributes to significant market growth.
   
• Furthermore, Germany's robust healthcare infrastructure and focus on innovative diagnostic technologies position it as a leader in advancing liquid biopsy solutions, ultimately improving patient outcomes across Europe.
   

China held a prominent position in Asia Pacific breast cancer liquid biopsy market, anticipating dominance throughout during the forecast period.
 

• China’s leadership in the Asia market is attributed to the increasing prevalence of breast cancer and the rising demand for early detection and personalized treatment options. The growing adoption of non-invasive diagnostic techniques, such as liquid biopsies, allows for real-time monitoring of tumor dynamics and treatment efficacy.
   
• Additionally, advancements in technology and supportive government initiatives aimed at improving healthcare infrastructure are further propelling market growth. As awareness of breast cancer management continues to rise, China’s dominance in the liquid biopsy market is expected to strengthen.
   

Brazil accounted for the highest revenue in the Latin American breast cancer liquid biopsy market.
 

• Brazil’s prominence is driven by a combination of increasing breast cancer incidence and a growing focus on early detection and personalized medicine.
   
• The country’s robust healthcare infrastructure, coupled with advancements in liquid biopsy technologies, facilitates access to innovative diagnostic solutions.
   
• Furthermore, rising awareness among healthcare providers and patients regarding the benefits of non-invasive testing methods is enhancing market growth. As Brazil continues to invest in cancer research and treatment options, its leadership in the market is expected to persist.
   

Saudi Arabia is poised to grow at a significant growth rate in the Middle East and African breast cancer liquid biopsy market.
 

• The projected growth in Saudi Arabia is driven by increasing awareness of breast cancer screening and advancements in diagnostic technologies.
   
• The government's focus on enhancing healthcare services and initiatives aimed at early detection and prevention are boosting demand for innovative testing methods.
   
• As healthcare providers adopt non-invasive approaches for monitoring and diagnosing breast cancer, the market is expected to expand rapidly.
   
• Furthermore, rising investments in research and development within the country will contribute to improving access to liquid biopsy solutions, solidifying Saudi Arabia's position in this market.
   

Breast Cancer Liquid Biopsy Market Share

The market is marked by intense competition among leading players who are concentrating on advancements in diagnostic technologies and innovative liquid biopsy solutions. Key companies are focused on innovation, investing heavily in research and development to enhance diagnostic accuracy and expand their product offerings. Strategic collaborations and partnerships are common, allowing firms to leverage complementary technologies and broaden market reach.
 

Additionally, rising awareness of non-invasive diagnostic techniques and supportive regulatory frameworks further intensify competition. Emerging players are also entering the market, contributing to a dynamic landscape that fosters advancements in liquid biopsy technologies. As the demand for early detection and personalized treatment options grows, maintaining a competitive edge through innovation and strategic positioning will be crucial for success.
 

Breast Cancer Liquid Biopsy Market Companies

Few of the prominent players operating in the breast cancer liquid biopsy industry include:

• Datar Cancer Genetics
• Epic Sciences
• F. Hoffmann-La Roche
• Genes2me
• Illumina
• Menarini Silicon Biosystems
• Myriad Genetics
• OncoDNA
• QIAGEN
• Sysmex
• System Biosciences
• Thermo Fisher Scientific
• Twist Bioscience
   

Breast Cancer Liquid Biopsy Industry News:

• In February 2024, Twist Bioscience launched the cfDNA Library Preparation Kit to advance liquid biopsy research, focusing on providing a reliable solution with enhanced accuracy and sensitivity. This launch signified enhancing liquid biopsy capabilities and facilitating personalized cancer treatment strategies by improving the reliability of cfDNA analysis in cancer.
   
• In August 2022, Guardant Health received U.S. FDA approval for its Guardant360 companion diagnostics (CDx) liquid biopsy test to identify advanced or metastatic breast cancer. This approval marked a significant advancement as the test became a CDx for selecting patients with unresectable or metastatic HER2-mutant non-small cell lung cancer (NSCLC).
   

The breast cancer liquid biopsy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Biomarkers

• Circulating tumor cells (CTCs)
• Cell-free DNA (cfDNA)
• Exosomes
• Other biomarkers

Market, By Products & Services

• Kits & reagents
• Services

Market, By Sample Type

• Blood
• Urine
• Other sample types

Market, By End Use

• Hospitals
• Cancer research centers
• Diagnostic centers
• Academic and research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE